D Saulites Kandevicas Private Practice
- Address
- Aldaru Str. 20/24, LV-3401 Liepāja, Latvia
D Saulites Kandevicas Private Practice - Cardiovascular Disease Research
D Saulites Kandevicas Private Practice is a clinical research facility specializing in cardiovascular disease studies, with particular expertise in lipid management and atherosclerotic cardiovascular disease (ASCVD). The practice participates in advanced Phase 3 clinical trials evaluating novel therapeutic approaches for patients with inadequate response to standard lipid-modifying therapies.
- Atherosclerotic cardiovascular disease (ASCVD) treatment optimization
- Advanced lipid-lowering therapies and CETP inhibition
- Major adverse cardiovascular event (MACE) prevention strategies
The research center focuses on investigating innovative interventions for patients with atherosclerotic heart and blood vessel disease, particularly those characterized by narrowing of arteries from buildup of plaque. Their clinical trial portfolio emphasizes evaluation of treatments targeting cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and coronary revascularization outcomes in high-risk cardiovascular populations requiring therapeutic advancement beyond conventional lipid management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Viatris Innovation GmbH1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 80 other sites in Latvia
Therapeutic Area Benchmark — Latvia
Select a therapeutic area to compare against other sites in Latvia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Latvia
Market Share
Country: Latvia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in D Saulites Kandevicas Private Practice
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR) | AbbVie Deutschland GmbH & Co. KG | Phase III | Not Recruiting | May 2016 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Upadacitinib | 2 | Unknown | 2016-05-10 | 2023-11-20 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.